The popularity of copyright’s blockbuster initially fueled a surge for the drug industry, however recent changes present a uncertain outlook for shareholders. Generic versions are eating into earnings, and persistent patent challenges add more difficulty to the situation. While specific companies may still see gains from related services, the gen